These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6733844)

  • 1. Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.
    Lu K; Savaraj N; Loo TL
    Cancer Chemother Pharmacol; 1984; 13(1):63-6. PubMed ID: 6733844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog.
    Lu K; Loo TL
    Cancer Res; 1980 May; 40(5):1427-30. PubMed ID: 7370981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione.
    Savaraj N; Lu K; Valdivieso M; Burgess M; Umsawasdi T; Benjamin RS; Loo TL
    Clin Pharmacol Ther; 1982 Mar; 31(3):312-6. PubMed ID: 7060314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog.
    Lu K; Loo TL
    Cancer Chemother Pharmacol; 1980; 4(4):275-9. PubMed ID: 7438330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation.
    Rosenberg LS; Carvlin MJ; Krugh TR
    Biochemistry; 1986 Mar; 25(5):1002-8. PubMed ID: 2870736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of homoharringtonine in dogs.
    Lu K; Savaraj N; Feun LG; Guo ZG; Umsawasdi T; Loo TL
    Cancer Chemother Pharmacol; 1988; 21(2):139-42. PubMed ID: 3349562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative structure-genotoxicity study of three aminoanthraquinone drugs and doxorubicin.
    Au WW; Butler MA; Matney TS; Loo TL
    Cancer Res; 1981 Feb; 41(2):376-9. PubMed ID: 7448780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of mitoxantrone in cancer patients.
    Alberts DS; Peng YM; Leigh S; Davis TP; Woodward DL
    Cancer Res; 1985 Apr; 45(4):1879-84. PubMed ID: 3978648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Amonafide in dogs.
    Lu K; McLean MA; Vestal ML; Newman RA
    Cancer Chemother Pharmacol; 1988; 21(2):134-8. PubMed ID: 3349561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical pharmacology of mitozantrone.
    Smyth JF; Macpherson JS; Warrington PS; Leonard RC; Wolf CR
    Cancer Chemother Pharmacol; 1986; 17(2):149-52. PubMed ID: 3719894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectroscopic evidence for anthracenedione antineoplastic agent self-association and complex formation with flavin nucleotides.
    Kharasch ED; Novak RF
    Arch Biochem Biophys; 1984 Nov; 234(2):497-512. PubMed ID: 6497384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of mitoxantrone in cancer patients.
    Savaraj N; Lu K; Manuel V; Loo TL
    Cancer Chemother Pharmacol; 1982; 8(1):113-7. PubMed ID: 7094196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics and metabolism of mitoxantrone in man.
    Ehninger G; Proksch B; Heinzel G; Schiller E; Weible KH; Woodward DL
    Invest New Drugs; 1985; 3(2):109-16. PubMed ID: 4019115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of dihydroxyanthraquinone and adriamycin on the survival of cultured Chinese hamster cells.
    Kimler BF; Cheng CC
    Cancer Res; 1982 Sep; 42(9):3631-6. PubMed ID: 7105035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent.
    Tatsuta N; Suzuki N; Mochizuki T; Koya K; Kawakami M; Shishido T; Motoji N; Kuroiwa H; Shigematsu A; Chen LB
    Cancer Chemother Pharmacol; 1999; 43(4):295-301. PubMed ID: 10071980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disposition of 6-ethyl-3-(1H-tetrazol-5-yl)-chromone, a new antiallergic agent, in the rat, guinea-pig, rabbit, dog and monkey.
    Kanai Y; Nakai Y; Nakajima N; Tanayama S
    Xenobiotica; 1979 Jan; 9(1):33-50. PubMed ID: 104449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between cytotoxicity and DNA damage in mammalian cells treated with anthracenedione derivatives.
    Locher SE; Meyn RE
    Chem Biol Interact; 1983 Sep; 46(3):369-79. PubMed ID: 6357512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and metabolism of the antitumor agent pyrazine-2-diazohydroxide in mouse and beagle dog.
    Moore DJ; Brodfuehrer JI; Wilke TJ; Powis G
    Cancer Chemother Pharmacol; 1988; 21(4):269-73. PubMed ID: 3370734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-(1-Oxyalkyl)-1,4-dioxy-9,10-anthraquinones: synthesis and evaluation of antitumor activity.
    Jin GZ; Song GY; Zheng XG; Kim Y; Sok DE; Ahn BZ
    Arch Pharm Res; 1998 Apr; 21(2):198-206. PubMed ID: 9875431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.